May 10, 2014
By Reuters Staff
A drug under development by Amgen Inc and AstraZeneca Plc met the goals of a Phase 3 study in patients with moderate-to-severe plaque psoriasis, the companies said on Friday.
The 661-patient trial of brodalumab met all primary and secondary endpoints for both of the evaluated doses, they said.
It showed that 83% of patients given the highest dose, and 60% of patients on a lower dose, achieved at least a 75% reduction in disease severity after 12 weeks, compared with about 3% of placebo patients.
Psoriasis affects 125 million people worldwide and about 7.5 million Americans, according to the National Psoriasis Foundation.
Brodalumab is designed to reduce inflammatory signaling by blocking the binding of interleukin-17 ligands to cell receptors.
Side effects in the Phase 3 brodalumab trial included head colds, upper respiratory tract infection and headache. Serious side effects occurred in 1.8% of patients in the high-dose group, 2.7% of patients in the low-dose group and 1.4% of the placebo group.
Amgen and AstraZeneca, which has spurned recent takeover offers from Pfizer Inc, are also conducting two head-to-head trials comparing brodalumab to Stelara, also known as ustekinumab, a psoriasis treatment sold by a unit of Johnson & Johnson.
(c) Copyright Thomson Reuters 2014. Click For Restrictions - http://about.reuters.com/fulllegal.asp